Insider Brief
- RetinaLogik raised $1.1M in funding and received Health Canada Class II medical device approval for its VR-AI-powered eye care platform, accelerating adoption across clinics.
- The portable headset enables more efficient visual field exams, reducing testing time, equipment costs by up to 90%, and improving accessibility with multilingual support.
- Backed by Alberta Innovates, UCeed Funds, and Spring Impact Capital, RetinaLogik plans to expand across North America, enhancing early detection and treatment of vision-threatening conditions.
PRESS RELEASE — RetinaLogik Inc., a Calgary-based startup, is proud to announce it has successfully completed a $1.1 million funding round and has received Health Canada’s Class II medical device approval for its cutting-edge technology.
These milestones will accelerate the adoption of RetinaLogik’s VR-AI-powered platform, enabling eye care professionals to perform essential tests — including visual field exams — more efficiently while enhancing the patient experience with a portable headset.
The device, which is ISO-13485 and MDSAP Certified as well as FDA registered, is designed with patient comfort in mind, offering a streamlined testing process that significantly reduces both the time required for exams and the cost of equipment. In fact, the RetinaLogik system can reduce upfront costs by up to 90% compared to traditional equipment. It also features multilingual support, helping to bridge communication gaps in the clinic.
Dr. Sarhan, CEO of RetinaLogik, expressed his enthusiasm about the progress: “Achieving these milestones marks a proud moment for our organization. We’ve developed a solution that not only makes eye care more efficient but also more affordable and accessible. With the support of our investors and partners, we’re excited to continue growing and improving the future of eye care for everyone. This is just the start, stay tuned for more!”
Nikhi Operating Partner, UCeed Funds, shared: “We have proudly supported the RetinaLogik team since their earliest stages and are thrilled to deepen our commitment by doubling down on our investment in the company. Over the past two years, the RetinaLogik team has built a groundbreaking VR platform that delivers unparalleled clinical reliability for functional eye exams.” This was also emphasized by Graham Day, Managing Partner, Spring Impact Capital: “Spring Impact Capital is proud to have co-led this round for RetinaLogik, which is proving strong market demand for its product. By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are set to make a meaningful impact on communities while achieving commercial success. We’re excited to support Abdullah, Julia, and the team in this next phase.”
This milestone wouldn’t be possible without the support from the community such as Alberta Innovates. Trevor Lynn, Vice Precident of Health in Alberta Innovates adds: “Alberta Innovates congratulates RetinaLogik on obtaining it’s Health Canada Class II licence through support from the Accelerating Innovations into CarE (AICE) program. This accomplishment is an example of Alberta’s success commercializing health innovation to improve the patient experience and enable easier patient care access in the community.”
With these milestones, RetinaLogik reaffirms its commitment to advancing high-quality vision screening and monitoring to provide more insights for specialists. The company plans to expand adoption of its platform across North America and beyond, helping to close critical gaps in eye care. By enabling earlier detection and treatment of vision-threatening conditions, RetinaLogik aims to prevent irreversible vision loss and improve patient outcomes.
For more information about the platform and RetinaLogik’s commitment to revolutionizing eye care, visit www.retinalogik.ca.
Contacts
[email protected]
(587) 741–4565
